Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025

Halle (Saale) / Munich, Germany, June 6, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical-stage company focused on creating small molecule drugs for inflammatory and fibrotic conditions, particularly kidney diseases, announced the presentation of meta-analysis data for varoglutamstat, its leading drug candidate, at the 62^nd ERA Congress of the European Renal Association in Vienna, Austria, today, June 6, 2025.

“We are very pleased that the Phase 2 program results were selected for presentation at the ERA 2025 congress. This provided Vivoryon with the opportunity to share the significant improvements in kidney function (eGFR) achieved with varoglutamstat with kidney experts in the scientific and medical community,” stated Frank Weber, MD, CEO of Vivoryon.

Presentation Highlights
Varoglutamstat is a novel glutaminyl cyclase (QPCT/L) inhibitor demonstrating strong anti-inflammatory and anti-fibrotic properties. Two independent Phase 2 studies, VIVIAD and VIVA-MIND, conducted in the EU and U.S., revealed a statistically significant and clinically relevant improvement in eGFR, a pre-defined kidney function parameter, within an elderly patient group. This improvement was consistently observed across both individual trials, confirmed by meta-analysis and pooled analysis, providing strong evidence for the finding. Statistically significant differences between varoglutamstat and placebo were initially noted at week 24 and persisted through week 96. The meta-analysis also indicated a notably larger effect size among study participants with diabetes compared to those without.

The planned next step is a dedicated Phase 2b trial focusing on patients with diabetic kidney disease (those with diabetes and chronic kidney disease stage 3b/4). The primary objective will be to assess the efficacy of varoglutamstat on eGFR in this patient population and to gather further data on its potential impact on proteinuria and other kidney-specific markers.

Presentation Details
Date: June 6, 2025
Presentation time: 8:15 am CEST as part of the focused oral session
Title: Varoglutamstat improves eGFR and offers a new approach to treat diabetic kidney disease (DKD): meta-analysis from two independent Phase 2 studies
Venue: Vienna, Austria
Presenter: Frank Weber, MD, CEO of Vivoryon Therapeutics

###

About Vivoryon Therapeutics N.V.
Vivoryon is a clinical-stage biotechnology company dedicated to developing innovative, small molecule-based therapies for inflammatory and fibrotic kidney disorders. Driven by a commitment to pioneering science and innovation, the Company aims to enhance patient outcomes by altering the progression of severe diseases through the modulation of the activity and stability of disease-relevant proteins. Varoglutamstat, Vivoryon’s lead program, is a proprietary, first-in-class, orally available QPCT/L inhibitor currently under evaluation for the treatment of diabetic kidney disease. 

Vivoryon Forward Looking Statements

This press release contains forward-looking statements regarding the business strategy, management plans, and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), including estimates and projections concerning the market for the Company’s products, forecasts, and statements regarding the potential availability of the Company’s products. Terms like “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should,” and “will,” and similar expressions related to the Company, are used to identify these forward-looking statements. These statements do not guarantee future performance but are based on the Management’s current expectations and assumptions about future events, trends, the economy, and other future conditions. These forward-looking statements involve known and unknown risks and uncertainties that could significantly affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies, or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. Therefore, undue reliance should not be placed on these statements. This press release does not list risk factors. Certain risk factors that may impact the Company’s future financial results are detailed in the Company’s published annual financial statements. This press release, including any forward-looking statements, is current as of its date, and the Company assumes no obligation to update any information or forward-looking statements contained herein, except as required by law.

For more information, please contact:

Investor Contacts
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email:

LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email:

Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email:

Attachment

“`